First Trust Advisors
ACHN

First Trust Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

First Trust Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-53,510
Closed -$221K – 2496
2016
Q4 		$221K Buy
+53,510
New +$284K ﹤0.01% 2342

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Trust Advisors's ACHN Position: Q1 2017 in Review

First Trust Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 53,510 shares — an estimated $221K sold.

First Trust Advisors first reported a position in ACHN in Q4 2016 and held it in 1 quarter. The position peaked at $221K in Q4 2016. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • First Trust Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • First Trust Advisors sold 53,510 Achillion Pharmaceuticals shares in Q1 2017, an estimated $221K.
  • First Trust Advisors first reported a position in Achillion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • First Trust Advisors's Achillion Pharmaceuticals position peaked at $221K in Q4 2016.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on First Trust Advisors's 13F filing for Q1 2017, filed 2 May 2017.